Upstream Bio, Inc.: Promising Clinical Developments and Strategic Positioning Drive Buy Rating

J.P. Morgan analyst Tessa Romero has maintained their bullish stance on UPB stock, giving a Buy rating on June 16.

Tessa Romero has given her Buy rating due to a combination of factors surrounding Upstream Bio, Inc.’s promising clinical developments and strategic positioning in the market. The company has successfully completed patient enrollment for its phase 2 VALIANT trial, which is evaluating the efficacy of verekitug in treating severe asthma. This milestone sets the stage for anticipated topline results in the first half of 2026, which could significantly impact the company’s valuation if positive.
Additionally, the upcoming results from the phase 2 VIBRANT trial, expected in the third quarter of 2025, will further assess verekitug’s potential in treating chronic rhinosinusitis with nasal polyps. Romero sees verekitug as a pivotal factor for Upstream Bio’s stock performance over the mid- to long-term. The potential for pipeline-in-a-product development and the validation from external data on competitive approaches like Tezspire further support her optimistic outlook on the stock.